Last $47.09 USD
Change Today -0.13 / -0.28%
Volume 6.0M
As of 8:04 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

100 Abbott Park Road

Abbott Park, IL 60064

United States

Phone: 847-937-6100

Fax:

Abbott Laboratories engages in the discovery, development, manufacture and sale of a line of health care products. Segments The company operates in four segments, including Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Established Pharmaceutical Products This segment’s products include a line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States. These products are generally sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from the company-owned distribution centers and public warehouses, depending on the market served. Certain products are co-marketed or co-promoted with, or licensed from, other companies. The principal products included in the therapeutic area portfolios of the Established Pharmaceutical Products segment are: gastroenterology products, including Creon, for the treatment of pancreatic exocrine insufficiency associated with various underlying conditions, including cystic fibrosis and chronic pancreatitis; Duspatal and Dicetel, for the treatment of irritable bowel syndrome or biliary spasm; Heptral, Transmetil, Samyr, and Donamet, for the treatment of intrahepatic cholestasis (associated with liver disease) or depressive symptoms; and Duphalac, for regulation of the physiological rhythm of the colon; women's health products, including Duphaston, for the treatment of various different gynecological disorders; and Femoston, a hormone replacement therapy for postmenopausal women; cardiovascular and metabolic products, including Lipanthyl and TriCor, for the treatment of dyslipidemia; Teveten and Teveten Plus, for the treatment of essential hypertension, and Physiotens, for the treatment of hypertension; and Synthroid, for the treatment of hypothyroidism; pain and central nervous system products, including Serc, for the treatment of Menière's disease and vestibular vertigo; and Brufen, for the treatment of pain, fever, and inflammation; and respiratory drugs and vaccines, including the anti-infective clarithromycin (sold under the trademarks Biaxin, Klacid, and Klaricid); and Influvac, an influenza vaccine. The Established Pharmaceutical Products segment directs its primary marketing efforts toward building a brand with key stakeholders, including consumers, pharmacists, physicians, and other healthcare providers. Government agencies are also major customers. Diagnostic Products This segment offers a line of diagnostic systems and tests manufactured, marketed, and sold worldwide to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, government agencies, alternate-care testing sites, and plasma protein therapeutic companies. In the United States, the segment's products are generally marketed and sold directly from the company-owned distribution centers, public warehouses and third-party distributors. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served. The principal products included in the Diagnostic Products segment are: immunoassay and clinical chemistry systems, including ARCHITECT and ABBOTT PRISM; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases, such as hepatitis and HIV; a line of hematology systems and reagents known as the Cell-Dyn series; the m2000, an instrument that automates the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents, including HIV, HBV, HCV, HPV, and CT/NG; the Vysis product line of genomic-based tests, including the PathVysion HER-2 DNA probe kit; the UroVysion bladder cancer recurrence kit; and the Vysis ALK Break Apart FISH Probe Kit, the only the U.S. Food and Drug Administration-approved companion diagnostic to Pfizer's approved non-small-cell lung cancer therapy XALKORI; IRIDICA, an instrument used to rapidly identify a range of infection-causing pathogens, i

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT:US $47.09 USD -0.13

ABT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $59.62 USD -0.84
Actavis plc $296.23 USD -1.08
Bristol-Myers Squibb Co $61.92 USD -0.38
Eli Lilly & Co $70.37 USD -0.75
Novo Nordisk A/S kr314.10 DKK -0.90
View Industry Companies
 

Industry Analysis

ABT

Industry Average

Valuation ABT Industry Range
Price/Earnings 42.2x
Price/Sales 3.5x
Price/Book 3.3x
Price/Cash Flow 25.1x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit www.abbott.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.